ALS Limited (CPBLF)
| Market Cap | 7.82B +46.6% |
| Revenue (ttm) | 2.11B +18.2% |
| Net Income | 179.31M +4,272.6% |
| EPS | 0.36 +4,374.6% |
| Shares Out | n/a |
| PE Ratio | 43.60 |
| Forward PE | 26.37 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 100 |
| Average Volume | 2,324 |
| Open | 14.50 |
| Previous Close | 16.11 |
| Day's Range | 14.50 - 16.11 |
| 52-Week Range | 10.95 - 18.19 |
| Beta | 1.16 |
| RSI | 61.49 |
| Earnings Date | May 18, 2026 |
About ALS Limited
ALS Limited engages in the provision of professional technical services primarily in the areas of testing, measurement, and inspection in Africa, Asia Pacific, Europe, the Middle East, North Africa, and the United States. It operates in two segments, Commodities and Life Sciences. The Commodities segment offers assaying and analytical testing, and metallurgical services for the mining and mineral exploration companies. Its testing and consulting services cover the resource life cycle, including exploration, feasibility, optimization, production... [Read more]
Financial Performance
In fiscal year 2025, ALS Limited's revenue was 3.00 billion, an increase of 21.85% compared to the previous year's 2.46 billion. Earnings were 256.20 million, an increase of 1886.05%.
Financial numbers in AUD Financial StatementsNews
ALS Limited Earnings Call Transcript: H1 2026
Revenue rose 13.3% to AUD 1.7 billion with strong organic growth and margin improvement. Upgraded FY 2026 guidance targets 6%-8% organic growth, with commodities and life sciences both contributing, and robust cash generation supporting investments and dividends.
ALS Limited Transcript: Investor Day 2025
A refreshed strategy focuses on disciplined capital allocation, digital transformation, and targeted growth in minerals and environmental sectors. AI and automation are driving efficiency and margin gains, while a strong M&A pipeline and sustainability commitments support long-term value creation.
ALS Limited Transcript: AGM 2025
Solid FY2025 results with 16% revenue growth, strategic investments in lab upgrades, and a strong focus on digital transformation and sustainability. Board transitions and remuneration practices were discussed, with shareholders engaging on governance, growth, and technology risks.
ALS Limited Earnings Call Transcript: H2 2025
Strong FY2025 results with 16% revenue growth and robust performance in minerals and life sciences. Major lab upgrades and a AUD 350 million equity raise will support future growth, with FY2026 targeting 5%-7% organic revenue growth and margin expansion.
ALS Limited Earnings Call Transcript: H1 2025
Underlying EBIT rose 2.1% to AUD 250 million, with revenue up 14% to AUD 1.4 billion, driven by strong Life Sciences growth and resilient Minerals margins. Integration of recent acquisitions is progressing, with robust cash flow and a focus on deleveraging and margin improvement.